Analytical Data
-
Gene name
CCNJL
- Application
-
Alternative Names
CCNJLCyclin-J-like protein
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8IV13
-
Expression Region
315-435aa
-
Molecular Weight
14.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of CCNJL (Cysteine-rich protein with a CCN domain and a Julius factor-like domain) recombinant protein has garnered significant interest in recent years due to its potential implications in cellular signaling, tissue repair, and various diseases. CCNJL is part of the CCN family of proteins, which are known to play crucial roles in cell proliferation, differentiation, and the extracellular matrix's remodeling. Initial research has suggested that CCNJL may be involved in regulating physiological processes such as angiogenesis and cell adhesion. Additionally, aberrant expression of CCNJL has been linked to several pathological conditions, including cancer and fibrosis, highlighting its potential as a therapeutic target. The recombinant production of CCNJL allows for detailed biochemical studies, enabling researchers to investigate its structure-function relationships and interactions with other cellular components. By characterizing CCNJL at the molecular level, scientists aim to unravel its biological significance and explore its utility in developing novel diagnostic and therapeutic strategies, ultimately advancing our understanding of complex biological systems and disease mechanisms. Through such interdisciplinary research, the scientific community hopes to harness the properties of CCNJL to improve health outcomes and develop targeted interventions for related diseases.
